Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
3 2 — — — 2 1 3 4 6
P/E ratio
0.00 0.00 — 14.07 9.39 0.00 0.00 0.00 5.11 0.97
Altman Z-Score
(0.14) (8.39) — 1.82 2.12 (0.95) (4.03) (3.67) (5.93) (8.83)
P/S ratio
6.17 211.43 — 3.52 2.61 3.69 3.13 1.15 5.99 3.94
P/FCF ratio
0.00 0.00 — 47.30 8.45 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(10.19) (20.17) — (1.34) 3.67 (3.25) (9.61) (9.10) (13.65) (20.15)
P/Operating CF
(13.51) (16.96) — 70.86 37.47 (23.01) (6.61) (22.85) 5.53 (8.44)
Beneish M-Score
4.91 — — — (2.50) (4.41) (2.77) (1.39) (3.21) (3.44)
P/B ratio
60.64 16.62 — 11.93 4.42 12.32 0.00 0.00 0.00 2.73
Price to Tangible BV
74.32 18.81 — 12.35 4.47 12.79 0.00 0.00 0.00 11.26
EV/Sales
6.04 200.86 — 3.53 2.33 4.04 4.47 2.55 17.89 4.89
EV/EBITDA
0.00 0.00 — 11.33 6.95 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(4.55) (2.41) — 44.36 7.18 (35.28) (3.92) (3.75) (23.09) (1.49)
EV/FCF
(4.43) (2.35) — 47.41 7.54 (34.10) (3.88) (3.73) (22.08) (1.48)
Quick Ratio
2.25 4.47 2.18 2.78 4.79 3.27 2.17 1.14 0.88 1.36
Current Ratio
2.86 5.12 2.54 2.98 5.27 3.64 2.75 1.43 1.21 1.47
Net Debt/EBITDA
0.22 0.11 (0.15) 0.01 (0.86) 0.03 (1.10) (1.78) (0.71) 0.76
Debt/Assets
56.17% 62.49% 103.64% 43.62% 48.00% 60.10% 97.96% 75.19% 59.07% 14.34%
Debt/Equity
5.18 3.33 (2.67) 1.70 1.44 4.18 (3.43) (2.45) (2.01) 0.61
Asset Turnover
0.97 0.01 0.00 1.40 0.76 0.43 0.36 0.46 0.05 0.12
Operating CF/Net income
1.98 0.84 0.76 0.32 1.17 0.13 0.83 0.74 (0.72) (0.82)
Capex/Depreciation
(2.17) (1.35) (0.24) (0.56) (2.50) (0.37) (0.55) (0.08) 0.00 0.00
Interest Coverage
(14.53) (24.30) (21.11) 6.12 7.39 (11.49) (7.91) (5.01) (18.60) (20.12)
ROE
(2,049.69%) (954.80%) 5,197.10% 269.68% 68.49% (151.62%) 1,470.09% 143.81% (17.52%) (473.47%)
ROA
(65.16%) (139.65%) (159.75%) 35.34% 21.15% (37.75%) (50.29%) (42.85%) 5.29% 47.54%
ROIC
0.00% (2,805.20%) 0.00% 63.58% 67.92% (185.69%) (113.10%) (78.30%) (1,795.44%) 0.00%
Return on Tangible Assets
(109.89%) (183.41%) (361.98%) 38.41% 20.93% (64.54%) (116.10%) (159.68%) 46.60% 248.32%
Average Days of Receivables
3.57 0.00 — 145.55 120.47 137.51 190.18 369.65 1,692.07 159.41
Research and Development Expense of Revenue
133.84% 10,436.31% 0.00% 26.45% 30.00% 111.19% 94.46% 42.54% 348.00% 258.20%
Selling, General and Administrative Expense of Revenue
27.14% 4,582.46% 0.00% 38.49% 29.23% 51.97% 94.05% 74.64% 475.51% 238.56%
Intangible Assets out of Total Assets
0.02 0.02 0.04 0.01 0.00 0.01 0.01 0.11 0.12 0.18
Share Based Compensation of Revenue
14.42% 2,146.34% 0.00% 9.43% 8.02% 15.73% 24.04% 16.76% 105.35% 40.23%
Graham Net Nets
0.00 0.03 — 0.03 0.17 0.02 (0.36) (1.17) (1.51) 0.06
Graham Number
0.00 0.00 — 6.59 12.80 0.00 12.24 10.90 0.00 4.14
Earnings Yield
(11.32%) (47.64%) — 7.11% 10.64% (24.19%) (44.18%) (81.85%) 19.57% 102.82%
Free Cash Flow Yield
(22.08%) (40.37%) — 2.11% 11.84% (3.22%) (36.81%) (59.47%) (13.53%) (83.84%)
Revenue per Share
4.54 0.03 0.00 5.11 6.66 4.33 2.72 2.73 0.23 0.36
Operating CF per Share
(6.03) (3.77) (2.45) 0.41 2.16 (0.50) (3.11) (1.86) (0.18) (1.18)
Capex per Share
(0.16) (0.09) (0.01) (0.03) (0.10) (0.02) (0.03) 0.00 0.00 0.00
Free Cash Flow per Share
(6.18) (3.86) (2.46) 0.38 2.06 (0.51) (3.13) (1.86) (0.18) (1.18)
Cash per Share
2.98 2.39 1.11 2.55 7.58 5.53 2.47 1.25 1.10 1.47
Shareholders Equity per Share
0.46 0.57 (0.59) 1.51 3.93 1.30 (1.77) (2.05) (1.15) 0.52
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.46 0.57 (0.59) 1.51 3.93 1.30 (1.77) (2.05) (1.15) 0.52
Free Cash Flow
(259.06) (204.86) (160.05) 26.53 146.91 (38.72) (243.16) (175.17) (20.44) (138.51)
Working Capital
105.11 117.08 51.17 228.04 621.83 437.00 242.54 143.86 58.60 66.32
Capital Expenditures
(6.51) (4.57) (0.79) (1.82) (7.23) (1.29) (2.04) (0.29) — —
Net Current Asset Value
2.36 13.40 (53.62) 39.30 206.80 20.72 (237.03) (347.40) (238.94) 9.38
EV/EBIT
0.00 0.00 — 11.67 7.08 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 2.94 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 — 11.64 7.94 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.28 0.27 0.49 0.56 0.29 0.44 0.42 0.74 2.05 2.92
Cash ROIC
(105.90%) (79.06%) (116.91%) 5.75% 11.98% (4.19%) (46.29%) (44.05%) (7.89%) (51.27%)
Accounts Receivable Turnover
111.21 0.00 — 4.95 3.18 2.33 1.81 1.39 0.14 0.60
Accounts Payable Turnover
0.00 0.00 0.21 0.83 1.83 3.67 5.06 6.80 0.27 0.72
Inventory Turnover
— — 0.03 2.98 1.39 1.41 1.83 3.14 0.26 3.74
Average Days of Payables
0.00 0.00 1,725.60 555.37 147.30 102.41 60.03 80.85 1,190.15 261.98
Days of Inventory on Hand
— — 187.18 209.60 428.63 238.57 202.03 143.72 175.95 83.81
Average Receivables
1.71 — — 71.93 149.52 140.03 116.49 185.24 191.43 70.38
Average Payables
25.04 18.15 15.50 20.64 20.59 15.68 13.84 23.37 31.84 19.19
Average Inventory
— — 129.33 5.73 27.02 40.94 38.22 50.70 33.41 3.69
Average Assets
195.43 170.55 131.04 254.20 625.29 760.49 580.09 555.23 539.07 353.44
Average Common Equity
6.21 24.94 (4.03) 33.31 193.09 189.35 (19.85) (165.42) (162.71) (35.49)

Fold the line items

Columns are period end dates